Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
GALTthis companyGalectin Therapeutics Inc.	$3.37	-8.67×	-2.11×	0×	-16.28×	-156.0%	0.0%	0.0%	0.0%	24.4%	-174.3%	-9.0%	-1.06×	-4.95×	-2.74×	2.42×	0.0%	2	-55.48	2	C
ALTAltimmune, Inc.	$2.20	-3.61×	1.41×	7,757.46×	-3.56×	-96.0%	100.0%	-230461.0%	-214861.0%	-39.2%	-35.4%	-21.2%	0.16×	0.09×	-57.76×	18.55×	0.0%	2	2.76	2	C+
AURAAura Biosciences, Inc.	$7.24	-3.1×	2.4×	0×	-2.73×	-88.8%	0.0%	0.0%	0.0%	-77.6%	-73.1%	-25.9%	0.13×	0.4×	0×	8.15×	0.0%	2	8.97	2	C+
DMACDiaMedica Therapeutics Inc.	$9.82	-11.37×	6.66×	0×	-10.97×	-96.7%	0.0%	0.0%	0.0%	-58.4%	-61.0%	-7.8%	0×	0.47×	0×	11.81×	0.0%	1	37.36	2	C
DSGNDesign Therapeutics, Inc.	$10.55	-7.69×	2.53×	0×	-7.55×	-97.5%	0.0%	0.0%	0.0%	-32.8%	-37.1%	-10.1%	0.01×	0.22×	0×	17.14×	0.0%	1	26.54	2	C
LBRXLB Pharmaceuticals Inc Common Stock	$43.40	-22.26×	1.87×	0×	-12.72×	-75.2%	0.0%	0.0%	0.0%	-8.4%	-9.9%	-6.3%	0.01×	9.91×	0×	41.44×	0.0%	2	25.27	2	C+
Peer median	—	-7.69×	2.4×	0×	-7.55×	-96.0%	0.0%	0.0%	0.0%	-39.2%	-37.1%	-10.1%	0.01×	0.4×	0×	17.14×	0.0%	2	25.27	2	—